Brexit fallout continues with batch testing concerns
Pharmaceutical Technology
AUGUST 12, 2022
In principle, the deal could create new opportunities for British pharma companies – not least the chance to work under a more supportive regulatory framework. Among the negative effects that have been reported are supply chain disruptions, skills shortages, issues around market authorisation, and added costs for pharma CMOs.
290 
Let's personalize your content